Tharimmune.

That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option …Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Companyâ s lead product candidate is HSB-1216, an …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Tharimmune Inc Registered Shs's market capitalization is $16.74 M by 17.51 M shares outstanding. Tharimmune Stock Snapshot. 2.95. Bid. 40.00. Bid Size. 3.00.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...

A high-level overview of Tharimmune, Inc. (THAR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.TH104 is a product which has been developed by embedding drug onto a proprietary transmucosal buccal film which adheres to the inside of the mouth. TH104 has key features which we believe make it an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The active molecule, nalmefene, has a dual ... Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Company Info Tharimmune Inc. 1200 Route 22 East. Suite 2000. Bridgewater New Jersey 08807. United States. Website. Map. Employees 2. Sector Biotechnology. About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno ...

Company Info Tharimmune Inc. 1200 Route 22 East. Suite 2000. Bridgewater New Jersey 08807. United States. Website. Map. Employees 2. Sector Biotechnology.

Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Tharimmune Inc (NASDAQ: THAR) released phase 1 data with TH104, a proprietary transmucosal buccal film. The first Phase 1 trial was a crossover study of TH104 transmucosal buccal film compared to ...According to FactSet, Tharimmune Inc’s share price will average $100.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 2749.0 percent from its previous closing price of $3.51. Analysts expect Tharimmune Inc stock to reach the higher price of $100.00, while the lowest price estimate is $100.00.

Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 17, 2023, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it effected a 1-for-25 …Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) ACCESSWIRE - Mon Nov 27, 2:00AM CST. BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology …

Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron med iated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an …

Tharimmune Inc. stock performance at a glance Check Tharimmune Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. THAR Stock PerformanceTharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis November 6, 2023; Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 202314.45%. Get the latest Tharimmune Inc (THAR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ...

Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...

About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.

Chg %. $2.8750. -0.1450. -4.80%. Tharimmune Inc. advanced stock charts by MarketWatch. View THAR historial stock data and compare to other stocks and exchanges.Tharimmune (NASDAQ:THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock. Each share of common stock is being sold at a public offering price of $1.00 ...Tharimmune's stock reverse split on the morning of Tuesday, November 21st 2023. The 1-25 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 ...Check Tharimmune Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. THAR Stock Performance. USD …THAR - Tharimmune, Inc. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 0.9510. -2.5590 (-72.91%) As of 03:05PM EST. Market open. Stock chart is not supported by your current browser. Gain ...Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...Tharimmune () stock is rising higher alongside a new licensing agreement. The company is going to handle the development of TH104. This news brings heavy trading to THAR stock on Tuesday.On Tuesday, Tharimmune Inc [NASDAQ:THAR] saw its stock jump 64.87% to $0.26. On the same session, the stock had its day’s lowest price of $0.2081, but rose to a high of $0.27. Over the last five days, the stock has gained 67.31%. Tharimmune Inc shares have fallen nearly -33.30% since the year began. Nevertheless, the stocks have fallen …Tharimmune's stock reverse split on the morning of Tuesday, November 21st 2023. The 1-25 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 ...Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ...

17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...How much is Tharimmune stock worth today? ( NASDAQ: THAR) Tharimmune currently has 17,511,839 outstanding shares. With Tharimmune stock trading at $0.21 per share, the total value of Tharimmune stock (market capitalization) is $3.68M. Tharimmune stock was originally listed at a price of $3.48 in Jan 12, 2022.Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting ...Instagram:https://instagram. is spacex going publicdm tickerhow to make money on coinbasehempacco stock 06-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ... tcnnf stock forecastforex brokers for small accounts Tharimmune, Inc. Analyst Report: AbbVie Inc. AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting ... cost of a bar of gold Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Nov 30, 2023 · About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. Sep 26, 2023 · Tharimmune is a hot topic on Tuesday after the company underwent a name change and also changed to the THAR stock ticker. Tharimmune is a hot topic on Tuesday after the company underwent a name ...